MEMORY B CELL RESPONSES FOLLOWING IMMUNISATION WITH POLYSACCHARIDE AND CONJUGATE QUADRIVALENT MENINGOCOCCAL ACYW135 VACCINES IN HEALTHY ADULT VOLUNTEERS

MEMORY B CELL RESPONSES FOLLOWING IMMUNISATION WITH POLYSACCHARIDE AND CONJUGATE QUADRIVALENT MENINGOCOCCAL ACYW135 VACCINES IN HEALTHY ADULT VOLUNTEERS

Bibliographic Details
Main Authors:	Maheshi, R, Elizabeth, C, Jaclyn, B, Snape, MD, Mushiya, M, Kathryn, H, Pollard, A
Format:	Journal article
Published:	2010

Similar Items

Safety and immunogenicity of quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135) compared with quadrivalent meningococcal conjugate vaccine (Menactra®) in Malian children
by: Samba O. Sow, et al.
Published: (2023-08-01)

Quadrivalent meningococcal conjugate vaccines.
by: Pace, D, et al.
Published: (2009)

Quadrivalent meningococcal conjugate vaccines
by: Pace, D, et al.
Published: (2009)

High-dimensional assessment of B-cell responses to quadrivalent meningococcal conjugate and plain polysaccharide vaccine.
by: O'Connor, D, et al.
Published: (2017)

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study
by: Timo Vesikari, et al.
Published: (2020-06-01)

Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naïve toddlers: A randomised, controlled trial
by: Markus Knuf, et al.
Published: (2022-11-01)

Meningococcal polysaccharide-protein conjugate vaccines.
by: Snape, MD, et al.
Published: (2005)

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT): A review of the evidence and expert opinion
by: Silvia Ricci, et al.
Published: (2023-12-01)

Randomized clinical trial to evaluate the immunogenicity of quadrivalent meningococcal conjugate and polysaccharide vaccines in adults in the United kingdom.
by: Ramasamy, M, et al.
Published: (2014)

Comparative Transcriptome Profiling of mRNA and lncRNA of Mouse Spleens Inoculated with the Group ACYW135 Meningococcal Polysaccharide Vaccine
by: Nan Zhu, et al.
Published: (2023-07-01)

Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older
by: David Neveu, et al.
Published: (2023-09-01)

Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines.
by: Pace, D, et al.
Published: (2007)

Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) Administered Concomitantly with Pneumococcal Conjugate Vaccine in Healthy Toddlers in the Russian Federation: a Phase III Randomized Study
by: L. S. Namazova-Baranova, et al.
Published: (2023-01-01)

Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers
by: Miguel Tregnaghi, et al.
Published: (2014-09-01)

Meningococcal polysaccharide-protein conjugate vaccines (vol 5, pg 21, 2005)
by: Snape, MD, et al.
Published: (2005)

No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales - Authors' reply
by: Snape, MD, et al.
Published: (2006)

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a Phase II randomized study
by: Judith Kirstein, et al.
Published: (2020-06-01)

Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study
by: Germán Áñez, et al.
Published: (2020-06-01)

Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged ≥59 years: A phase III randomized study
by: Corwin A. Robertson, et al.
Published: (2023-01-01)

Current safety issues with quadrivalent meningococcal conjugate vaccines
by: Tanya R. Myers, et al.
Published: (2018-05-01)

Meningococcal meningitis presenting postinfant group B meningococcal immunisation
by: So, N, et al.
Published: (2018)

Safety and immunogenicity of a single dose of a quadrivalent meningococcal conjugate vaccine (MenACYW–D): a multicenter, blind-observer, randomized, phase III clinical trial in the Republic of Korea
by: Dong Soo Kim, et al.
Published: (2016-04-01)

Erratum: Meningococcal polysaccharide-protein conjugate vaccines (Lancet Infective Diseases (2005) 5 (21-30)
by: Snape, MD, et al.
Published: (2005)

NMR Assays for Estimating the O‑Acetyl Content of Meningococcal Polysaccharide Serogroup A in Quadrivalent Conjugate Vaccine Formulation
by: Silvia Martini, et al.
Published: (2019-07-01)

Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
by: Perrett, K, et al.
Published: (2009)

An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine
by: Pavitra Keshavan, et al.
Published: (2018-10-01)

Correction to “NMR Assays for Estimating the O‑Acetyl Content of Meningococcal Polysaccharide Serogroup A in Quadrivalent Conjugate Vaccine Formulation”
by: Silvia Martini, et al.
Published: (2019-09-01)

Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations
by: Khatami, A, et al.
Published: (2012)

Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations.
by: Khatami, A, et al.
Published: (2012)

Studying dependence levels of the antibodies to capsular polysaccharides of meningococcus revealing by developed acyw135, ac and a latex diagnostics in the sera of Ethiopia population
by: А V Kharitonova, et al.
Published: (2008-09-01)

Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults
by: Hoan Jong Lee, et al.
Published: (2014-11-01)

CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells.
by: Kelly, D, et al.
Published: (2006)

Efficacy and Safety of Quadrivalent Conjugate Meningococcal Vaccines: A Systematic Review and Meta-Analysis
by: Andrea Conti, et al.
Published: (2023-01-01)

Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine
by: Sara Viksmoen Watle, et al.
Published: (2021-08-01)

W135 Meningococcal Disease in Africa
by: Andrew J. Pollard, et al.
Published: (2003-11-01)

Baseline polysaccharide-specific antibodies may not consistently inhibit booster antibody responses in infants to a serogroup C meningococcal protein-polysaccharide conjugate vaccine.
by: Blanchard-Rohner, G, et al.
Published: (2012)

Baseline polysaccharide-specific antibodies may not consistently inhibit booster antibody responses in infants to a serogroup C meningococcal protein-polysaccharide conjugate vaccine
by: Blanchard-Rohner, G, et al.
Published: (2012)

W135 Meningococcal Disease in Africa
by: Pollard, A, et al.
Published: (2003)

Real-world evidence of quadrivalent meningococcal conjugate vaccine safety in the United States: a systematic review
by: Tracy a Becerra-Culqui, et al.
Published: (2021-05-01)

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial.
by: Read, R, et al.
Published: (2014)